AstraZeneca reported positive results from clinical trial programs for Brilinta and Farxiga, causing stock to jump 3.4 percent.

AstraZeneca made strides toward the company’s goal of adding heart failure to the conditions that can be treated by Farxiga, putting the diabetes drug ahead of a rival medicine from Eli Lilly.

The FDA approved Gadavist for use in cardiac magnetic resonance imaging to assess myocardial perfusion and late gadolinium enhancement in adults with known or suspected CAD.

People who track their daily steps may not only be more active, they may also be less likely to develop health problems that lead to events like heart attacks or broken bones, a new study suggests.

For people without heart disease, taking a daily aspirin to prevent heart attacks and strokes may increase the risk of severe brain bleeding to the point where it outweighs any potential benefit, a research review suggests.

PhaseBio Pharmaceuticals’ antiplatelet drug PB2452 received Breakthrough Therapy designation from the U.S. FDA.